.jpg)
Bioxcel Therapeutics Inc (NASDAQ: BTAI) received a Buy rating and a $25 price target from H.C. Wainwright analyst Ram Selvaraju today. The company’s shares closed yesterday at $7.02, close to its 52-week low of $6.76.
Selvaraju observed:
“Intelligence; Initiating at Buy and $25 Price Target Stock Data 05/02/2018 Price $7.02 Exchange NASDAQ Price Target $25.00 52-Week High $16.68 52-Week Low $6.76 Enterprise Value (M) $53.9 Market Cap (M) $110 Public Market Float (M) 3.8 Shares Outstanding (M) 15.4 3 Month Avg Volume 109,370 Balance Sheet Metrics Cash (M) $55.9 Total Debt (M) $0.0 Total Cash/Share $3.63 Book Value/Share $(0.10) EPS Diluted Full Year – Dec 2017A 2018E 2019E 1Q — (0.21) (0.39) 2Q — (0.39) (0.47) 3Q — (0.30) (0.55) 4Q — (0.30) (0.59) FY (0.47) (1.22) (2.03) 12 11 10 9 8 7 6 MAR-18 APR-18 MAY-18 2.5 2 1.5 1 0.5 0 Vol. (mil) Price Unlocking efficiency in drug development. BioXcel Therapeutics is an artificial intelligence (AI)-driven biopharmaceutical company headquartered in Branford, CT, which is deploying the power of big data analytics and machine learning to optimize drug development.”
According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -6.3% and a 35.9% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Bioxcel Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $20.40.
See today’s analyst top recommended stocks >>
The company has a one-year high of $11.94 and a one-year low of $6.76. Currently, Bioxcel Therapeutics Inc has an average volume of 107K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focuses on drug development. The firm’s two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in Branford, CT.
